We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: thrombosis
MedXY News
EnglishTag

thrombosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Lipids and Modulates Procoagulant Function: Implications for Thrombosis Management
CardiologyACKR3acylcarnitines

Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Lipids and Modulates Procoagulant Function: Implications for Thrombosis Management

By MedXY|Sep 17, 2026

Pharmacological activation of CXCR7 regulates platelet lipid metabolism, preserves mitochondrial function, and reduces procoagulant activity, offering a novel therapeutic strategy to mitigate thrombotic risk in cardiovascular diseases.

Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications
Clinical UpdatesGPIbαGPIIb/IIIa

Histidine-Rich Glycoprotein as a Modulator of Platelet Adhesion and Aggregation: Mechanistic Insights and Clinical Implications

By MedXY|Aug 23, 2026

Histidine-rich glycoprotein (HRG) directly modulates platelet adhesion and aggregation by binding platelet receptors GPIbα and GPIIb/IIIa, competing with key ligands VWF and fibrinogen, thus attenuating thrombus formation; reduced HRG in se

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury
CardiologyCD36 receptorMetrnl

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury

By MedXY|Aug 21, 2026

Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.

HIF2 Activation in Cardiac Vasculature: A Novel Mechanistic Insight into Kawasaki Disease’s Cardiovascular Complications
CardiologyinflammationCoronary Artery Remodeling

HIF2 Activation in Cardiac Vasculature: A Novel Mechanistic Insight into Kawasaki Disease’s Cardiovascular Complications

By MedXY|Aug 18, 2026

This study reveals how HIF2 activation drives coronary artery remodeling, inflammation, and thrombosis in a mouse model mirroring severe Kawasaki disease, uncovering new therapeutic targets for coronary complications.

Molecular Mutations and Cardiovascular Risks Shape Prognosis in Triple-Negative Essential Thrombocythemia
Cardiologycardiovascular riskMutation profile

Molecular Mutations and Cardiovascular Risks Shape Prognosis in Triple-Negative Essential Thrombocythemia

By MedXY|Jul 15, 2026

This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for perso

Olfactory Receptor Signaling as a Novel Antiplatelet Strategy: OR2L13 Activation, HSP27 Phosphorylation, and Cytoskeletal Control of Arterial Thrombosis
CardiologyHSP27olfactory receptor

Olfactory Receptor Signaling as a Novel Antiplatelet Strategy: OR2L13 Activation, HSP27 Phosphorylation, and Cytoskeletal Control of Arterial Thrombosis

By MedXY|Jun 10, 2026

A 2026 Circulation study identifies OR2L13 agonism as a first-in-class platelet inhibitory strategy that suppresses aggregation and arterial thrombosis through HSP27-dependent actin remodeling without an apparent hemostatic penalty in precl

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
CardiologyCardiologyclinical trial

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

By MedXY|Mar 9, 2026

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b

Lower-Intensity Anticoagulation During Venovenous ECMO: A Pilot RCT Shows Feasibility and a Signal Toward Less Bleeding
Cardiologyanticoagulationbleeding

Lower-Intensity Anticoagulation During Venovenous ECMO: A Pilot RCT Shows Feasibility and a Signal Toward Less Bleeding

By MedXY|Nov 5, 2025

A 3-center randomized pilot trial found that randomized allocation to low- versus moderate-intensity anticoagulation during venovenous ECMO is feasible, with lower major bleeding rates in the low-intensity arm and no clear excess of thrombo

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story